ArticleFrontiers in immunology2026
Porcine Parvovirus virus-like particle vaccine induces long-term humoral immunity by recruiting T follicular helper and germinal center B cell responses.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine parvovirus (PPV) is a major pathogen causing reproductive disorders in sows and remains widely prevalent worldwide. In recent years, PPV has undergone rapid mutations and frequently co-infects with other pathogens, making vaccination the most effective preventive measure. Our previous study showed that co-expression of the chaperone protein Tf16 and VP2 in prokaryotic cells could produce highly immunogenic PPV virus-like particles (VLPs). However, whether these VLP vaccines can induce durable immune memory through sustained antibody recall responses has not been fully elucidated. In this study, mice were immunized with VLPs formulated with ISA 201 VG adjuvant, and the responses of follicular helper T cells (Tfh) and germinal center B cells (GC B cells) were analyzed. The results demonstrated that recombinant VLPs significantly enhanced Tfh and GC B cell responses after the third immunization compared to a commercial inactivated vaccine. More importantly, PPV VLPs effectively induced the generation of specific long-lived plasma cells (LLPCs) and memory B cells (MBCs). These findings enhance our understanding of PPV VLP immunogenicity and may inform the design of more efficacious PPV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.